On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...

Amgen (NASDAQ:AMGN – Free Report) had its target price cut by UBS Group from $335.00 to $326.00 in a report released on Thursday, Benzinga reports. They currently have a neutral rating on the medical ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen (NASDAQ:AMGN – Get Free Report) will be releasing its earnings data before the market opens on Wednesday, October 30th.

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron Werber has given his Buy rating due to a combination of ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Amgen AMGN reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11 ...

As we can see, the immunology drug Enbrel, osteoporosis drug Prolia, bone tumor therapy Xgeva, thrombocytopenia therapy Nplate ... data would have on Amgen's share price, because of the size ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335 ... offset by higher Nplate, Blincyto, and Repatha sales, the analyst tells investors in a research note.